Company Overview - Mingde Biological's stock price is reported at 20.97 yuan, down 0.11 yuan from the previous trading day, representing a decline of 0.52% [1] - The stock reached a high of 21.00 yuan and a low of 20.76 yuan during the trading session, with a trading volume of 26,255 hands and a transaction amount of 55 million yuan [1] Industry Information - The company operates in the medical device industry, focusing on the research, development, production, and sales of in vitro diagnostic reagents and related instruments [1] - Its product range includes testing for infectious diseases, cardiovascular diseases, kidney diseases, and diabetes among other areas [1] Shareholder and Fund Flow Data - As of August 8, 2025, the total number of shareholders for Mingde Biological is reported to be 24,532 [1] - On August 20, the net outflow of main funds was 1.3974 million yuan, with a cumulative net outflow of 12.1727 million yuan over the past five trading days [1]

参考上交所《上市公司治理准则》、港交所《环境、社会及管治守则》等文件，搜狐财经迭代完善各行 业ESG测评体系标准，并以最新标准为依托，以2024年公司ESG报告为主要数据来源，对公司环境资 源、社会责任及公司管治进行了评价。 编者按：ESG年报解读为搜狐财经及价值公司100联合发起的针对各公司ESG报告披露情况的解读专 栏。 本文为"明德生物"篇。 网 资料来源：明德生物官 研究员 | 张子豪 荧光PCR技术赋能检测方案，明德生物体外诊断创新提速 近期，基孔肯雅病毒在中国呈现输入性病例引发局部传播、防控压力持续的态势，主要集中在华南地 区。病毒主要通过埃及伊蚊和白纹伊蚊叮咬传播。 8月12日，明德生物发布了基孔肯雅病毒及蚊媒病原体核酸检测解决方案，采用荧光PCR方法，灵敏度 可达50至200拷贝/毫升，最快1小时内生成检测结果。且该方案已在湖北省内及我国西南地区的疾控中 心与医院中投用。此消息被看作是公司在体外诊断业务产品创新层面的积极动态。 明德生物的基孔肯雅病毒核酸检测解决方案对该病的防控具有快速诊断、精准溯源、降低传播风险的核 心作用，同时也体现了该公司在在技术投入、团队建设、专利布局及产品转化等方面的 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., indicating a significant disparity between its price-to-earnings (PE) ratio and the industry average [1][2] - As of August 15, the closing price of Mingde Biological was 20.77 yuan, with a PE ratio of 124.46, which is substantially higher than the industry average of 56.58 and the median of 39.97 [1][2] - The company's total market capitalization stands at 4.829 billion yuan, ranking it 108th in the medical device industry based on PE ratio [1][2] Group 2 - In terms of capital flow, on August 15, Mingde Biological experienced a net outflow of 11.45 million yuan, contributing to a total outflow of 41.45 million yuan over the past five days [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 69.96 million yuan, reflecting a year-on-year increase of 14.76%, while the net profit was a loss of approximately 3.66 million yuan, a decline of 111.43% year-on-year [1] - The gross profit margin for the company is reported at 16.37% [1]

Core Viewpoint - Mingde Biological's stock closed at 20.99 yuan, down 2.01%, with a rolling PE ratio of 125.77 times, indicating a significant premium compared to the industry average [1] Company Summary - Mingde Biological focuses on the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - For Q1 2025, the company reported revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, reflecting a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Mingde Biological at the 108th rank within the industry [1] - As of Q1 2025, there are 2 institutional investors holding shares in Mingde Biological, with a total holding of 123,100 shares valued at 0.02 million yuan [1]

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Core Viewpoint - The article discusses the outbreak of Chikungunya fever in China and globally, highlighting the urgent need for effective detection and prevention measures due to the lack of specific treatments and vaccines [2][3]. Group 1: Current Situation - As of July 23, 2025, Foshan reported a total of 3,645 confirmed cases of Chikungunya fever, with the Shunde District accounting for 3,317 cases, an increase of 383 cases from the previous day [2]. - The World Health Organization (WHO) has warned that 119 countries and regions are experiencing virus transmission, with approximately 5.5 million people at risk of infection, potentially straining healthcare systems [2]. Group 2: Prevention and Control - There are currently no specific drugs or vaccines for Chikungunya fever; the primary prevention strategy is mosquito control, including eliminating breeding sites and using personal protective measures [3]. - The clinical features of Chikungunya fever include acute fever, severe joint pain, and rash, with higher risks for children, the elderly, and immunocompromised individuals [3]. Group 3: Diagnostic Methods - Common diagnostic methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, with specific timelines for sample collection to ensure accurate results [4]. - Currently, there are no approved test kits for Chikungunya fever in China, which poses a challenge for timely diagnosis [4]. Group 4: Market Opportunities - Several domestic companies, including DaAn Gene, Wanfu Biology, and Shengxiang Biology, are developing Chikungunya fever detection solutions based on PCR methodologies, with others exploring high-throughput sequencing and antigen-antibody detection methods [5]. - The ongoing outbreak is expected to accelerate the accumulation of clinical data for these detection products, potentially speeding up their approval and market entry [5].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The number of confirmed cases of Chikungunya fever is rapidly increasing, with 3,645 cases reported in Foshan as of July 23, 2025, including a daily increase of 383 cases in Shunde District [1]. - The World Health Organization (WHO) has warned that 119 countries and regions are at risk of virus transmission, with approximately 5.5 million people facing infection risk [1]. - There are currently no specific drugs or vaccines available for Chikungunya fever, making mosquito control the primary prevention strategy [2]. - Multiple companies have launched testing solutions for Chikungunya fever, and the approval of these products is expected to accelerate [3]. Summary by Sections Industry Overview - Chikungunya fever is caused by the Chikungunya virus (CHIKV) and primarily transmitted by Aedes mosquitoes, with symptoms including acute fever and severe joint pain [2]. - The absence of effective treatment and vaccines necessitates supportive care and preventive measures such as mosquito control [2]. Testing Solutions - Common testing methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, but no test kits have been approved for sale in China [2]. - Companies like DaAn Gene, Wanfu Biology, and others have developed PCR-based testing solutions, while others are exploring high-throughput sequencing methods [3]. Investment Opportunities - The report suggests focusing on companies that have developed Chikungunya testing solutions, including DaAn Gene, Wanfu Biology, and others [3].

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].

Group 1 - The number of confirmed cases of Chikungunya fever in Shunde, Guangdong has reached 2,934, primarily affecting Lecong, Beijiao, and Chen Village, all of which are mild cases [1][2] - The World Health Organization has issued a warning regarding the potential for widespread outbreaks of Chikungunya fever, with 119 countries and regions reporting cases, putting approximately 5.5 million people at risk [2][3] - Local governments in Guangdong are actively promoting mosquito control measures, including public announcements urging citizens to eliminate mosquito breeding sites and participate in coordinated mosquito eradication efforts [2][3] Group 2 - The "mosquito repellent concept" has gained traction in the capital markets, with stocks related to mosquito control and testing reagents seeing significant increases [5][6] - Companies such as Rainbow Group and Kangzhi Pharmaceutical have experienced stock price surges, while others like Runben Co., Shanghai Jahwa, and Qingsong Co. have also seen gains [6] - Several companies, including Rendu Biotech and Mindray, have highlighted their mosquito-borne virus testing products, indicating a growing market interest in diagnostic tools for diseases like Chikungunya [6]

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - For Q1 2025, the company reported a revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company stood at 16.37% [1] Market Position - As of July 23, the company's stock closed at 22.03 yuan, with a PE ratio of 132.01, marking a new low in 318 days [1] - The total market capitalization of the company is 5.122 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 53.52, with a median of 37.14, placing Mingde Biological at the 108th position in the industry ranking [1][2] Shareholder Information - As of July 10, 2025, the number of shareholders for Mingde Biological is 24,757, a decrease of 81 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]